Cannabidiol is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Status Epilepticus. According to GlobalData, Phase I drugs for Status Epilepticus have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol overview

Cannabidiol (Epidiolex , Epidyolex) is a phytocannabinoid, one of the active cannabinoid identified within the Cannabis plant accounting for up to 40% of the Cannabis plant's extract, acts as an anti-epileptic agent. It is formulated as a solution for oral route of administration. Epidiolex is indicated for the treatment of seizures associated with Lennox-gastaut syndrome or dravet syndrome in patients 2 years of age and older and Rett syndrome and also as an adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older or it is also indicated for tuberous sclerosis complex (TSC) in patients 1 year of age and older. Cannabidiol (Epidiolex) is under development for the treatment of electrical status epilepticus of sleep (ESES), tuberous sclerosis complex in patients age 1 month to less than 12 months, epilepsy with myoclonic atonic seizures, Lennox-Gastaut syndrome (LGS) Dravet syndrome, blepharospasm, schizophrenia, autism spectrum disorder (pervasive developmental disorder), tuberous sclerosis complex, anorexia nervosa, Sturge-Weber syndrome, infantile spasm, tremor in Parkinson's Disease, heroin use disorder, opioid use disorder, neonatal hypoxic-ischemic encephalopathy (NHIE), developmental and epileptic encephalopathy. It was under development for Rett syndrome and schizophrenia related psychotic disorder.

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.